PreludeDx points to clinical study for risk assessment test

2021 02 24 22 29 5379 Breast Cancer 20210224225528 20220322220342

Molecular diagnostics developer PreludeDx said that a new clinical study published in the International Journal of Radiation Oncology · Biology · Physics showed that its DCISionRT Residual Risk Subtype (RRt) analysis identified ductal carcinoma in situ (DCIS) patients who had a much higher recurrence risk following breast-conserving surgery and radiation therapy.

In the study, researchers evaluated the 10-year recurrence risk in 926 women diagnosed with DCIS and treated with breast-conserving surgery with or without radiation therapy.

Patients in the RRt group had a 42% risk of recurrence after breast-conserving surgery and a significantly elevated recurrence rate of 14.7% after breast-conserving surgery and radiation therapy. As a result, the risk profile of these patients may warrant intensified or alternative therapy considerations, according to the company.

Page 1 of 96
Next Page